ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "risk assessment"

  • Abstract Number: 0015 • ACR Convergence 2023

    Genetic Predisposition to a Positive Antinuclear Antibody Test Is Not Associated with Increased Risk of Disease

    Gul Karakoc1, Ge Liu1, Jacy Zanussi2, Cecilia Chung2, Jorge Gamboa1, Jonathan Mosley1, Nancy Cox1, C. Michael Stein1 and Vivian Kawai1, 1Vanderbilt University Medical Center, Nashville, TN, 2University of Miami, Miami, FL

    Background/Purpose: Antinuclear antibodies (ANA) are biomarkers that are frequently used in the diagnosis of common autoimmune (AI) disorders, but are also present in ~12-20% of…
  • Abstract Number: 0740 • ACR Convergence 2023

    Renal Arteriosclerosis in Index Lupus Nephritis Biopsies Predicts Future Cardiovascular Disease

    Shivani Garg1, Brad Astor2, S. Sam Lim3, Amish Raval2, Weixiong Zhong2, Sarah Panzer2, Brad Rovin4 and Christie M. Bartels2, 1Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 2University of Wisconsin, School of Medicine and Public Health, Madison, WI, 3Emory University, Atlanta, GA, 4Ohio State University, Columbus, OH

    Background/Purpose: Patients < 40 years old with lupus nephritis (LN) face 42-fold higher risk of cardiovascular disease (CVD) compared to peers. Traditional CVD risk calculators…
  • Abstract Number: 2408 • ACR Convergence 2023

    The Use of the Southend GCA Probability Score (GCAPS) in Assessing the Risk of Giant Cell Arteritis in Australian Ophthalmological and General Medical Hospital Cohorts

    Eloise Norman1, Clare Fraser2, Mitchell Lawlor3 and Anthony Sammel4, 1Prince of Wales Hospital, Randwick, Australia, 2Save Sight Institute, The University of Sydney, Sydney, Australia, 3Sydney and Sydney Eye Hospital, Sydney, Australia, 4The Prince of Wales Hospital, Sydney, Australia

    Background/Purpose: The rate of positive temporal artery biopsies (TAB) in patients with suspected giant cell arteritis (GCA) varies widely, indicating the need for better pre-test…
  • Abstract Number: 0131 • ACR Convergence 2023

    Identifying Antinuclear Antibody Positive Individuals at Risk for Systemic Autoimmune Disease: Development and Validation of a Real-Time Risk Model

    April Barnado, Ryan Moore, Hank Domenico, Sarah Green, Alex Camai, Ashley Suh, Bryan Han, Katherine Walker, Audrey Anderson, Lannawill Caruth, Anish Katta, Allison McCoy and Daniel W. Byrne, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Up to 20% of the general population has a positive ANA without having autoimmune disease. Currently, no tools exist to help clinicians interpret the…
  • Abstract Number: 0744 • ACR Convergence 2023

    Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus

    May Choi1, Hongshu Guan2, Kazuki Yoshida3, Benjamin Kargere4, Jack Ellrodt5, Emma Stevens2, Tianrun Cai2, Brendan Everett2, Brittany Weber2 and Karen Costenbader6, 1University of Calgary, Calgary, AB, Canada, 2Brigham and Women's Hospital, Boston, MA, 3Takeda, Boston, MA, 4Williams College, Boston, MA, 5Williams College, Williamstown, MA, 6Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Cardiovascular disease (CVD) risk is elevated in patients with SLE but underestimated by current general population prediction algorithms that do not include SLE-related variables.…
  • Abstract Number: 2454 • ACR Convergence 2023

    Endometriosis Increase Risk of Antiphospholipid Syndrome: A Propensity Score Matched Cohort Study

    Zhiyong Chen1, Shiow-Ing Wang2, James Cheng-Chung Wei3 and Sheng-Ming Dai1, 1Department of Rheumatology and Immunology, Shanghai Sixth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, 2Institute of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan, 3Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan

    Background/Purpose: Patients with endometriosis have a variety of autoimmune abnormalities. Our objective was to investigate the risk of incident antiphospholipid syndrome (APS) in patients with…
  • Abstract Number: 0132 • ACR Convergence 2023

    Feasibility of a Real-Time Risk Model to Identify Antinuclear Antibody Positive Individuals at Risk for Systemic Autoimmune Disease

    April Barnado, Ryan Moore, Hank Domenico, Sarah Green, Alex Camai, Ashley Suh, Bryan Han, Katherine Walker, Audrey Anderson, Lannawill Caruth, Anish Katta, Allison McCoy and Daniel W. Byrne, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Positive antinuclear antibodies (ANAs) cause diagnostic dilemmas for clinicians across multiple specialties. We previously developed and validated a risk model using a de-identified electronic…
  • Abstract Number: 1078 • ACR Convergence 2023

    Outcomes of COVID-19 Infection in Hospitalized Autoimmune Patients and Transplant Patients on Immunosuppression

    Yashswee KC1 and Rochella Ostrowski2, 1Loyola University, Oakpark, IL, 2Loyola University Medical Center, Maywood, IL

    Background/Purpose: Coronavirus disease 2019 (COVID-19) can have varying outcomes. Patients with chronic conditions or immunosuppression experience more severe illness. Both organ transplant recipients and patients…
  • Abstract Number: 2521 • ACR Convergence 2023

    Understanding Age as a Risk Factor for Complications After Total Knee Arthroplasty: What Can We Learn from Machine Learning?

    Bella Mehta1, Yi Yiyuan2, Chloe Heiting3, Kaylee Ho2, Susan Goodman3, Peter Sculco3, Fei Wang2, Rich Caruana4, Peter cram5 and Said Ibrahim6, 1Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 2Weill Cornell Medicine, New York, NY, 3Hospital for Special Surgery, New York, NY, 4Microsoft, Redmond, WA, 5The University of Texas Medical Branch, Galveston, TX, 6Northwell Health, New Hyde Park, NY

    Background/Purpose: Rates of total knee arthroplasty (TKA) in the United Stateshave risen, coupled with increasing demand for TKAs in younger patients.1Althoughrates of postoperative complications in…
  • Abstract Number: 0201 • ACR Convergence 2023

    Tolerability and Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases – A Prospective Longitudinal Study over 12 Months

    Ioana Andreica1, Gianna Chierergo2, Stefania Reale2, Benjamin Wilde3, Styliani Tsiami4, David Kiefer4, Philipp Sewerin4, Hilal Kavruk5, Dimitra Karagkiozidou2, Barbara Guminski4, Andreas Kribben3, Xenofon Baraliakos6, Juergen Braun4 and Uta Kiltz7, 1Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 2Rheumazentrum Ruhrgebiet, Herne, and Ruhr-Universität Bochum, Herne, Germany, 3Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany, 4Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, 5Rheumazentrum Ruhrgebiet, Herne, and Ruhr-Universität Bochum, Düsseldorf, Germany, 6Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 7Rheumazentrum Ruhrgebiet, Herne, Germany

    Background/Purpose: Herpes zoster (HZ) is common in the elderly, with a lifetime risk of 25%. The primary risk factors for HZ are advanced age and…
  • Abstract Number: 1272 • ACR Convergence 2023

    Immunomodulators and Risk for Breakthrough COVID-19 After a Third SARS-CoV-2 mRNA Vaccine Among Patients with Rheumatoid Arthritis: A Cohort Study

    Abigail Schiff1, Xiaosong Wang1, Naomi Patel2, Yumeko Kawano1, Jennifer Hanberg3, Emily Kowalski1, Claire Cook2, Kathleen Vanni1, Grace Qian1, Katarina Bade4, Alene Saavedra1, Shruthi Srivatsan2, Zachary Williams2, Rathnam Venkat1, Zachary Wallace5 and Jeffrey Sparks6, 1Brigham and Women's Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital, Boston, MA, 5Massachusetts General Hospital, Newton, MA, 6Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: In August 2021, the CDC recommended a third SARS-CoV-2 mRNA vaccine dose to complete the initial vaccine series for immunosuppressed patients who had previously…
  • Abstract Number: 2555 • ACR Convergence 2023

    Cluster Analysis Reveals Subgroups in Patients with Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Implication for Long-term Prognosis Prediction

    YuFang Ding1, Qian Wang1, Xinping Tian2, Mengtao Li2, xiaofeng Zeng1 and Jiuliang zhao2, 1Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: Serologically active clinically quiescent (SACQ) is a clinical state of systemic lupus erythematosus (SLE) characterized by high levels of serologic markers without clinical activity.…
  • Abstract Number: 0232 • ACR Convergence 2023

    Incident Gout After Recombinant Zoster Vaccination in Adults Aged ≥65 Years in the USA

    Susan dosReis1, Chengchen Zhang1, Alejandro Amill-Rosario1, Abree Johnson1, Haeyoung Lee1, O’Mareen Spence2, Driss Oraichi2, Harry Seifert2, Valentine Franck3, Susan Gamble2 and Huifeng Yun2, 1University of Maryland School of Pharmacy, Baltimore, MD, 2GlaxoSmithKline, Rockville, MD, 3GlaxoSmithKline, Wavre, Belgium

    Background/Purpose: In pre‑licensure clinical trials, numerical differences in gout cases between the recombinant zoster vaccine (RZV) and placebo groups have been observed. However, real-world evidence…
  • Abstract Number: 1288 • ACR Convergence 2023

    Frailty Is Associated with Higher Risk of Readmission in Patients with Rheumatoid Arthritis

    Waqas Tahir1, Yenny Rosli2, Christopher Leung3, K Wysham4, Jiha Lee5, Radjiv Goulabchand6, Una Makris7, Siddharth Singh8 and Namrata Singh9, 1Mayo Clinic, Jacksonville, FL, 2University of Washington, Seattle, WA, 3Georgetown University School of Medicine, Washington, DC, 4VA Puget Sound/University of Washington, Seattle, WA, 5University of Michigan, Ann Arbor, MI, 6University of California San Diego, La Jolla, CA, 7UT Southwestern Medical Center and Dallas VA, Dallas, TX, 8University of California San Diego, San Diego, CA, 9University of Washington, Bellevue, WA

    Background/Purpose: With the advent of new therapies and increasing life expectancy, there is a rising number of older adults living with rheumatoid arthritis (RA). Patients…
  • Abstract Number: 2584 • ACR Convergence 2023

    Gut Microbiome and Intestinal Inflammation in Preclinical Stages of Rheumatoid Arthritis

    Benoît Thomas P. GILBERT1, Raul Yhossef TITO TADEO2, Céline LAMACCHIA1, Olivia STUDER1, Delphine COURVOISIER1, Jeroen RAES3 and Axel Finckh4, 1Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, 2Center for Microbiology, VIB, Leuven. Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium, 3Center for Microbiology, VIB, Leuven. Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, Katholieke Universiteit Leuven., Leuven, Belgium, 4HUG, Geneva, Switzerland

    Background/Purpose: We attempted to replicate and expand previous findings of an increased abundance of Prevotellaceae in early untreated Rheumatoid Arthritis (RA) or its preclinical stages,…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology